Nexentis Technologies Inc. Common Stock
Market Cap
4.1M
Short interest (May 15)
3.1%
Borrow Fee
17.63%
↓ 9.2%
Available Shares
20K
↑ 26.7%
Price Chart
Company Overview
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.